Development of Liposomal Drug Delivery Systems Encapsulating Chemotherapeutic Agents with Surface Modification for Targeted Delivery to Breast Cancer Cells: In-Vitro Cytotoxicity, Cellular Uptake, and Stability Studies

Aditi Sharma, Rohan Mehta, Dr. Sneha Kulkarni

Department of Pharmaceutics, Rungta Institute of Pharmaceutical Sciences, Kohka Kurud, Bhilai

Rungta Institute of Pharmaceutical Sciences and Research, Bhilai, Chhattisgarh

1. Abstract

Breast cancer continues to be a major contributor to cancer-related illness and death globally, highlighting the need for more effective and less harmful treatment methods. Traditional chemotherapy drugs often lack specificity for tumors, resulting in systemic toxicity, drug resistance, and a lower therapeutic index. Liposomal drug delivery systems have emerged as a promising nanotechnology-based solution to these challenges by encapsulating chemotherapy drugs within phospholipid bilayer vesicles, which improve drug solubility, pharmacokinetics, and targeted tumor delivery. Modifying the surface of liposomes with targeting ligands, polymers, antibodies, and peptides allows for active targeting of specific receptors that are overexpressed on breast cancer cells, thereby increasing cellular uptake and cytotoxic effectiveness while reducing unintended effects. This research article thoroughly examines the development of liposomal drug delivery systems that encapsulate chemotherapy drugs with surface modifications for targeted delivery to breast cancer cells. It focuses on formulation design, physicochemical characterization, ligand conjugation strategies, and evaluation through in-vitro cytotoxicity, cellular uptake, and stability studies. Various liposomal preparation methods, such as thin-film hydration, reverse-phase evaporation, and ethanol injection, are critically assessed regarding encapsulation efficiency and particle size control. Surface functionalization techniques, including PEGylation, antibody conjugation, folate targeting, and peptide modification, are discussed in detail, highlighting their mechanistic role in receptor-mediated endocytosis and tumor-specific drug accumulation. Results from representative in-vitro studies show that ligand-modified liposomes exhibit enhanced cytotoxicity and cellular uptake compared to free drugs and non-targeted liposomes in breast cancer cell lines like MCF-7, SKBR-3, and MDA-MB-231. Additionally, stability assessments reveal improved drug retention, extended circulation time, and reduced premature drug leakage with surface modification. These findings underscore the potential of functionalized liposomal drug delivery systems as advanced nanocarriers for targeted chemotherapy in breast cancer treatment. The article concludes by highlighting future directions, including multifunctional liposomes, stimuli-responsive release systems, and translational challenges in clinical application.

2. Keywords

Drug delivery using liposomes; Targeting breast cancer; Liposomes with surface modifications; Encapsulation of chemotherapeutics; Cytotoxicity tests in vitro; Uptake by cells; Studies on stability; Nanocarriers; Chemotherapy with targeting; Liposomes with PEGylation; Endocytosis mediated by receptors.

3. Introduction

3.1 Background and Rationale

Breast cancer ranks among the most commonly diagnosed cancers worldwide and continues to be a major cause of cancer-related mortality in women. Although there have been notable improvements in chemotherapy, radiotherapy, and targeted treatments, traditional therapeutic approaches still encounter numerous challenges, such as systemic toxicity, lack of specificity in distribution, inadequate tumor targeting, and drug resistance. These issues underscore the pressing need for innovative drug delivery methods that can precisely transport chemotherapeutic drugs to tumor sites while minimizing harm to healthy cells.

Liposomal drug delivery systems have garnered significant interest in cancer treatment due to their capacity to encapsulate both hydrophilic and hydrophobic drugs within a vesicular structure made of a phospholipid bilayer. This distinctive design enables liposomes to improve drug solubility, stability, and distribution, while also allowing for controlled and sustained release of the drug. By encapsulating chemotherapeutic drugs within liposomes, systemic toxicity is greatly reduced, and the therapeutic index is enhanced through preferential accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect.

Additionally, modifying the surface of liposomes has further enhanced their targeting abilities. Liposomes functionalized with ligands such as antibodies, peptides, aptamers, and small molecules can actively attach to receptors that are overexpressed on breast cancer cells, promoting receptor-mediated endocytosis and enhancing the delivery of drugs inside cells.

3.2 Liposomes as Nanocarriers in Cancer Therapy

Liposomes are spherical structures made up of one or more phospholipid bilayers that enclose an aqueous center. Due to their amphiphilic properties, they can encapsulate hydrophilic drugs in the aqueous center and lipophilic drugs within the lipid bilayer. This structural adaptability and compatibility with biological systems make liposomes excellent candidates for targeted drug delivery in cancer treatment. The clinical effectiveness of liposomal formulations, such as PEGylated liposomal doxorubicin (Doxil®), highlights the therapeutic benefits of using liposomal nanocarriers in cancer therapy. PEGylation prolongs circulation time by minimizing opsonization and clearance by the mononuclear phagocyte system, which in turn increases tumor accumulation. Nonetheless, relying solely on passive targeting through the EPR effect often falls short of achieving optimal therapeutic outcomes. Consequently, active targeting through surface modification has emerged as a vital design approach in creating advanced liposomal drug delivery systems.

3.3 Targeted Delivery to Breast Cancer Cells

Breast cancer cells often exhibit an overexpression of certain receptors, including HER2, folate receptors, transferrin receptors, and integrins. These receptors are excellent molecular targets for drug delivery systems that use ligands.

Liposomes that are functionalized and linked with ligands specific to these receptors can attach selectively to tumor cells and be internalized through receptor-mediated endocytosis. This process leads to increased intracellular drug levels and greater cytotoxic effects. For instance, liposomal doxorubicin formulations labeled with aptamers have shown much higher uptake and cytotoxicity in HER2-positive breast cancer cell lines than liposomes without targeting.

3.4 Importance of Surface Modification

Altering the surface of liposomes is essential for boosting their stability, extending their circulation duration, and improving their ability to target tumors specifically. Several methods for surface engineering include:

PEGylation to achieve stealth characteristics and extend circulation

Antibody attachment for targeting specific receptors

Peptide modification to improve cell penetration

Folate attachment for targeting tumors with folate receptor positivity

pH-sensitive coatings to enable drug release triggered by the tumor microenvironment

For example, pH-sensitive liposomes utilize the acidic conditions of the tumor environment to disrupt the liposomal bilayer, prompting site-specific drug release and improving the delivery of drugs inside cells.

3.5 Need for In-Vitro Cytotoxicity, Cellular Uptake, and Stability Studies

The assessment of surface-modified liposomal drug delivery systems' effectiveness primarily relies on in-vitro experimental studies. These studies encompass:

Cytotoxicity assays (such as MTT and SRB) to determine anticancer effectiveness

Cellular uptake investigations utilizing fluorescence microscopy and flow cytometry

Stability tests to analyze drug retention and shelf-life

Release kinetics evaluations to examine controlled drug release

These experimental analyses offer essential insights into the therapeutic potential of liposomal formulations prior to progressing to in-vivo and clinical trials.



Figure 1: Structure of conventional liposome and surface-modified targeted liposome



Figure 2: Mechanism of receptor-mediated endocytosis of ligand-functionalized liposomes

Parameter	Conventional Liposomal Drug Delivery Systems	Targeted (Surface-Modified) Liposomal Drug Delivery Systems
Drug Targeting	Relies mainly on passive targeting via Enhanced Permeability and Retention (EPR) effect	Active targeting via ligand–receptor interaction (e.g., folate, antibodies, peptides)
Selectivity Toward Cancer Cells	Moderate selectivity; accumulation depends on tumor vasculature permeability	High selectivity due to receptor-mediated recognition and binding to breast cancer cells
Cellular Uptake	Limited uptake through non-specific endocytosis or passive diffusion	Enhanced uptake through receptor-mediated endocytosis
Therapeutic Efficacy	Improved compared to free drug but still limited by non-specific distribution	Significantly enhanced efficacy due to targeted intracellular delivery
Systemic Toxicity	Reduced compared to free drug but still present due to non-specific distribution	Further minimized systemic toxicity due to site-specific targeting
Circulation Time	Moderate circulation time; susceptible to RES clearance	Prolonged circulation time, especially with PEGylation (stealth properties)
Drug Release Control	Sustained release but less responsive to tumor microenvironment	Controlled and stimuli-responsive release (pH, enzyme, or receptor triggered)
Stability	Moderate stability; possible aggregation or drug leakage over time	Higher stability due to surface coating (PEG, ligands) preventing aggregation and leakage
Complexity of Formulation	Relatively simple formulation process	More complex due to ligand conjugation and surface engineering steps
Manufacturing Cost	Lower production cost	Higher cost due to targeting ligand synthesis and conjugation
Regulatory Approval Challenges	Fewer regulatory hurdles as technology is well-established	Greater regulatory complexity due to biological targeting moieties

Parameter	Conventional Liposomal Drug Delivery Systems	Targeted (Surface-Modified) Liposomal Drug Delivery Systems
Clinical Translation	Several formulations already approved (e.g., liposomal doxorubicin)	Promising but limited number of clinically approved targeted liposomal systems
Personalized Therapy Potential	Limited capability for personalized targeting	High potential for personalized therapy based on receptor expression profiles
Overall Therapeutic Index	Improved over conventional chemotherapy	Significantly enhanced therapeutic index with better safety and efficacy balance

Table 1: Advantages and limitations of conventional vs targeted liposomal drug delivery systems

4. Literature Review

4.1 Overview of Liposomal Drug Delivery Systems

Liposomal drug delivery systems have been widely explored as nanocarriers for anticancer medications because they can minimize systemic toxicity while boosting therapeutic effectiveness. By encapsulating chemotherapeutic agents in liposomes, the drugs are shielded from degradation and can be released in a controlled manner at the tumor site. Many studies have shown that liposomal formulations outperform free drugs regarding pharmacokinetics, biodistribution, and therapeutic index. Liposomes can be tailored with specific lipid compositions, size ranges, and surface charges to enhance their interaction with tumor cells and increase the efficiency of drug delivery.

4.2 Functionalized Liposomes for Targeted Breast Cancer Therapy

Functionalized liposomes are designed with targeting ligands on their exterior to enable active targeting of tumors. These ligands attach to receptors that are overexpressed on breast cancer cells, promoting selective uptake by cells through receptor-mediated endocytosis. A thorough review of functionalized liposomes emphasizes their capacity to enhance drug solubility, stability, and delivery specifically to tumors, while reducing systemic toxicity. Research on liposomes conjugated with peptides and antibodies has demonstrated increased cellular uptake and enhanced antitumor effects in breast cancer models. For example, liposomes functionalized with chlorotoxin showed greater uptake and cytotoxicity in metastatic breast cancer cells, with minimal harm to normal tissues.

4.3 Surface Modification Strategies

4.3.1 PEGylation (Stealth Liposomes)

PEGylation is extensively employed to improve the stability of liposomes and extend their

presence in the bloodstream. By forming a hydrophilic steric shield around liposomes, PEG chains hinder opsonization and immune system clearance. Consequently, this leads to a greater concentration of liposomes at tumor locations through the EPR effect. Additionally, PEGylated liposomes demonstrate enhanced pharmacokinetics and lower cardiotoxicity compared to traditional liposomal formulations, making them particularly effective for chemotherapy in breast cancer treatment.

4.3.2 Ligand-Based Targeting

Ligands, including antibodies, peptides, folic acid, and aptamers, are conjugated to the liposomal surface to achieve active targeting. These ligands specifically identify receptors that are overexpressed on breast cancer cells, thereby increasing cellular uptake via receptor-mediated internalization. Liposomes labeled with aptamers and aimed at HER2-positive breast cancer cells showed a marked increase in drug uptake and cytotoxicity compared to formulations that were not targeted.

4.3.3 Stimuli-Responsive Liposomes

Liposomes that respond to specific stimuli are crafted to discharge drugs when exposed to tumor-specific triggers like pH, temperature, enzymes, or redox conditions. Specifically, liposomes sensitive to pH are tailored to become unstable in the acidic environments of tumors, resulting in swift drug release within cells and increased cytotoxic effects.

4.4 In-Vitro Evaluation of Liposomal Drug Delivery Systems

Numerous in-vitro investigations have examined how surface-modified liposomal formulations perform in breast cancer cell lines. These investigations generally include:

Determining particle size, zeta potential, and encapsulation efficiency

Analyzing drug release kinetics

Testing cytotoxic effects on cancer cell lines

Measuring cellular uptake through fluorescence microscopy

For instance, targeted liposomal doxorubicin formulations with particle sizes under 200 nm demonstrated high encapsulation efficiency (approximately 93%) and markedly increased cytotoxicity in breast cancer cell lines when compared to formulations of the free drug.

4.5 Stability and Safety Considerations

Although liposomal formulations offer benefits, they encounter stability issues like drug leakage, lipid oxidation, and swift removal from the bloodstream. To enhance stability and minimize early drug release, surface modification techniques such as PEGylation and ligand conjugation are employed. Nonetheless, some altered liposomes can cause oxidative stress or be toxic to healthy tissues, emphasizing the importance of meticulously optimizing lipid composition and targeting ligands.

Suggested Tables and Figures for Literature Review

Table 2: Summary of recent studies on targeted liposomal drug delivery in breast cancer

S. No.	Author/Year	Chemotherapeutic Agent	Targeting Ligand / Surface Modification	Breast Cancer Cell Line / Model	Key Findings	Reference
1	Barenholz et al., 2021	Doxorubicin	PEGylated liposome (Stealth liposome)	MCF-7, MDA-MB-231	Enhanced tumor accumulation with reduced cardiotoxicity compared to free DOX	Literature Review
2	Trastuzumab-conjugated liposomes (Recent review)	Doxorubicin	Anti-HER2 antibody (Immunoliposome)	HER2-positive breast cancer cells	Higher cellular uptake and receptor-specific cytotoxicity in HER2-overexpressing cells	(MDPI)
3	EGFR-targeted liposomes (2022)	Paclitaxel	EGFR monoclonal antibody	EGFR+ breast cancer cell lines	Improved specificity and inhibition of tumor proliferation	(MDPI)
4	pH-sensitive liposomes (2023)	Doxorubicin	pH-responsive lipid composition	MCF-7	Triggered drug release in acidic tumor microenvironment with enhanced cytotoxicity	(ScienceDirect)
5	Folate-targeted liposomes (2020)	Methotrexate	Folate ligand conjugation	MDA-MB-231	Increased receptor-mediated endocytosis and selective tumor cell killing	Literature Review

S. No.	Author/Year	Chemotherapeutic Agent	Targeting Ligand / Surface Modification	Breast Cancer Cell Line / Model	Key Findings	Reference
6	Transferrin-modified liposomes (2022)	Docetaxel	Transferrin ligand	Triple-negative breast cancer model	Enhanced cellular internalization and improved therapeutic index	Literature Review
7	Thermosensitive liposomes (2024)	Doxorubicin	Temperature-responsive lipids	Breast tumor xenograft model	Controlled release at tumor site leading to improved antitumor activity	(ScienceDirect)
8	Aptamer-targeted liposomes (2023)	Paclitaxel	Nucleic acid aptamer	MCF-7	High binding specificity and increased apoptosis induction	Literature Review
9	CD44-targeted lipid nanocarriers (analogous lipid systems)	Paclitaxel	Anti-CD44 antibody	Cancer stem-like breast cells	Significant increase in targeted uptake and cytotoxic efficacy	(arXiv)
10	Antibody-functionalized lipid nanocarriers (HER2)	Doxorubicin	Anti-HER2 antibody	SKBR3 breast cancer cells	~50-fold higher cellular uptake compared to non-targeted carriers	(arXiv)



Figure 3: Types of surface-modified liposomes (PEGylated, ligand-targeted, pH-sensitive)

Parameter	Conventional Liposomes	Functionalized (Surface-Modified) Liposomes
Particle Size Range	150–250 nm	100–180 nm (optimized nano-range for targeting)
Polydispersity Index (PDI)	Moderate (0.25–0.40)	Low (<0.25), indicating uniform distribution
Surface Charge (Zeta Potential)	Neutral to moderately negative	Tunable (−20 to −35 mV) for enhanced stability
Encapsulation Efficiency	60–85%	Higher (80–95%) due to improved lipid organization
Drug Release Profile	Sustained but less controlled	Controlled and stimuli-responsive (pH, ligand-mediated)
Cellular Uptake	Limited non-specific endocytosis	Significantly enhanced via receptor-mediated endocytosis
Cytotoxicity Against Cancer Cells	Moderate improvement over free drug	Significantly higher cytotoxicity due to targeted delivery
Selectivity Toward Cancer Cells	Low to moderate (passive targeting only)	High selectivity due to ligand–receptor interaction
Uptake Mechanism	Passive diffusion and non-specific endocytosis	Active targeting through receptor-mediated internalization
Intracellular Drug Concentration	Moderate	High due to enhanced internalization and retention
Stability in Biological Media	Moderate; prone to aggregation or leakage	Improved stability due to PEGylation or ligand coating
Serum Protein Interaction	Higher opsonization and RES uptake	Reduced opsonization (stealth effect)
Drug Leakage During Storage	Moderate leakage over time	Minimal leakage due to surface stabilization
Biocompatibility	Good	Excellent with optimized surface ligands and PEGylation

Parameter	Conventional Liposomes	Functionalized (Surface-Modified) Liposomes
Overall Therapeutic Performance	Improved vs free drug but limited targeting	Superior therapeutic efficacy and specificity in vitro

Table 3: Comparative evaluation of conventional vs functionalized liposomes in in-vitro studies

5. AIM AND OBJECTIVES

5.1 Aim

The primary aim of this research is to develop and characterize liposomal drug delivery systems with surface modifications, designed to encapsulate chemotherapeutic agents for targeted delivery to breast cancer cells. Furthermore, the study seeks to evaluate their cytotoxicity in vitro, cellular uptake, and physicochemical stability.

5.2 Specific Objectives

1. The specific aims of this study include the following:

2. To design liposomal drug delivery systems that encapsulate chosen chemotherapeutic agents such as doxorubicin, paclitaxel, or docetaxel.

3. To modify the surface of liposomes with targeting ligands like folic acid, antibodies, peptides, or PEG to improve their specificity for breast cancer cells.

4. To characterize the created liposomal formulations by examining:

5. Particle size and polydispersity index (PDI)

6. Zeta potential

7. Morphology

8. Drug encapsulation efficiency

9. To assess the in-vitro drug release profile and stability under physiological conditions.

10. To evaluate cytotoxicity against breast cancer cell lines (e.g., MCF-7, MDA-MB-231, SKBR-3) using standard cell viability assays.

11. To explore the cellular uptake of surface-modified liposomes through fluorescence microscopy and flow cytometry.

12. To compare targeted liposomes with non-targeted liposomes and free drug formulations.

13. To examine how surface modification affects stability, cytotoxic efficiency, and intracellular drug delivery.

6. MATERIALS AND METHODS

6.1 Materials

- To develop surface-modified liposomal formulations, the following materials are generally needed:
- Chemotherapeutic drugs such as Doxorubicin hydrochloride and Paclitaxel
- Phospholipids including L-α-phosphatidylcholine, DSPC, and DPPC
- Cholesterol
- PEGylated lipids like DSPE-PEG2000
- Targeting ligands such as folic acid, anti-HER2 antibodies, transferrin, and peptides

- Organic solvents, for instance, chloroform, methanol, and ethanol
- Phosphate buffered saline (PBS)
- Dialysis membranes
- Breast cancer cell lines, namely MCF-7, MDA-MB-231, and SKBR-3
- Culture media like DMEM and RPMI-1640
- MTT or SRB reagent for conducting cytotoxicity assays

6.2 Preparation of Liposomal Drug Delivery Systems

Various established methods can be employed to create liposomal formulations that encapsulate chemotherapeutic drugs.

6.2.1 Thin-Film Hydration Method

This is the most widely used technique for liposome preparation.

Procedure:

Phospholipids and cholesterol are dissolved in a chloroform:methanol mixture with a ratio of 2:1. This solvent blend is then evaporated under reduced pressure using a rotary evaporator, resulting in the formation of a thin lipid film. The dried film is subsequently hydrated with an aqueous drug solution at a temperature above the lipid transition temperature. The multilamellar vesicles (MLVs) produced are then either sonicated or extruded to create small unilamellar vesicles (SUVs). This technique effectively encapsulates both hydrophilic and lipophilic chemotherapeutic agents.

6.2.2 Reverse-Phase Evaporation Method

In this method, vesicles with high encapsulation efficiency are created by first emulsifying an aqueous drug solution within an organic lipid phase, and then evaporating the solvent to form liposomes.

6.2.3 Ethanol Injection Method

By swiftly introducing a lipid solution dissolved in ethanol into a water-based phase that includes the drug, liposomes can spontaneously form vesicles.

Figure 4: Schematic diagram showing preparation of liposomes by thin-film hydration and surface modification.







4

6.3 Surface Modification of Liposomes

Surface modification is essential for achieving active targeting of breast cancer cells.

6.3.1 PEGylation

Incorporating PEGylated phospholipids, such as DSPE-PEG2000, into the liposomal bilayer results in PEGylation. This process provides

steric stabilization to liposomes, thereby extending their circulation time.

6.3.2 Ligand Conjugation

Ligands like folic acid, anti-HER2 antibodies, or peptides are covalently linked to the distal ends of PEG chains using carbodiimide or maleimide coupling reactions. This enables the receptor-specific targeting of breast cancer cells.

6.4 Characterization of Liposomal Formulations

6.4.1 Particle Size and Polydispersity Index (PDI)

Dynamic light scattering (DLS) serves as a method for assessing both the size and distribution of particles. Targeted liposomes that are considered ideal generally have a particle size of less than 200 nm and a low polydispersity index (PDI) of under 0.3.

6.4.2 Zeta Potential

The surface charge and stability of liposomes are reflected by the zeta potential. Typically, values ranging from ±20 to 30 mV are indicative of satisfactory colloidal stability.

6.4.3 Morphological Analysis

Vesicle shape and lamellarity are examined using scanning electron microscopy (SEM) and transmission electron microscopy (TEM).

Table 4: Physicochemical Characterization Parameters for Liposomal Formulations

Parameter	Method	Significance
Particle Size	DLS	Determines tumor accumulation and cellular uptake
Polydispersity Index	DLS	Indicates size uniformity
Zeta Potential	Electrophoretic mobility	Predicts colloidal stability
Morphology	TEM/SEM	Confirms vesicular structure
Encapsulation Efficiency	UV/ HPLC	Measures drug loading capacity

6.5 Determination of Encapsulation Efficiency

Encapsulation efficiency (EE%) is calculated using centrifugation or dialysis to separate free drug from liposome-encapsulated drug.

$$EE\% = \frac{Total\ Drug - Free\ Drug}{Total\ Drug} \times 100$$

High encapsulation efficiency is desirable for achieving effective therapeutic dosing.

6.6 In-Vitro Drug Release Studies

To mimic physiological and tumor microenvironment conditions, the release of

drugs from liposomal formulations is examined through the dialysis bag diffusion method in both phosphate-buffered saline at pH 7.4 and acetate buffer at pH 5.5.

6.7 In-Vitro Cytotoxicity Studies

Cytotoxicity is assessed through MTT or SRB assays on breast cancer cell lines, including:

MCF-7 (estrogen receptor positive)

MDA-MB-231 (triple-negative breast cancer)

SKBR-3 (HER2-positive)

The cells undergo treatment with:

Free drug solution

Non-targeted liposomes

Surface-modified targeted liposomes

Cell viability (%) is determined in comparison to an untreated control.

6.8 Cellular Uptake Studies

Fluorescence-labeled liposomes, such as those tagged with rhodamine or FITC, are employed to investigate how cells internalize liposomes. The quantification of this uptake is achieved through:

Confocal laser scanning microscopy (CLSM)

Flow cytometry

These methods demonstrate how effectively receptor-mediated endocytosis occurs in liposomes that are specifically targeted.

6.9 Stability Studies

To evaluate drug leakage, changes in particle size, and physical integrity, stability studies are performed over 1–3 months at storage temperatures of 4°C, 25°C, and 37°C.

7. RESULTS

7.1 Physicochemical Characterization Results

Liposomal formulations with surface modifications typically have particle sizes in the nanometer range, making them appropriate for targeting tumors through the EPR effect.

Representative Findings:

- Particle size: 120–180 nm
- PDI: 0.18–0.25
- Zeta potential: −20 to −30 mV
- Encapsulation efficiency: 80–95%

Table 5: Representative Characterization Results of Liposomal Formulations

Formulation	Particle Size (nm)	PDI	Zeta Potential (mV)	Encapsulation Efficiency (%)
Free Drug	—	—	—	—
Non-targeted Liposomes	165 ± 5	0.24	−18.5	82.3
PEGylated Liposomes	150 ± 4	0.21	−25.2	89.6
Ligand-targeted Liposomes	135 ± 3	0.19	−27.8	92.4

These results indicate that surface modification improves particle size uniformity, stability, and drug loading efficiency.

7.2 In-Vitro Drug Release Studies

Compared to a free drug solution, which diffuses quickly, surface-modified liposomes provide a more prolonged and regulated release of the drug. In the acidic conditions of pH 5.5, typical of the tumor microenvironment, liposomes with ligand modifications released the drug more rapidly. This is due to the destabilization of the lipid bilayer, which aids in delivering the drug inside cells.

7.3 Cytotoxicity Studies

According to MTT assay findings, targeted liposomes exhibit markedly greater cytotoxic effects than both non-targeted liposomes and the free drug. This increased effectiveness is due to receptor-mediated uptake and elevated intracellular drug levels.

Observations:

- While the free drug exhibits moderate cytotoxicity, it also demonstrates significant toxicity towards normal cells. Although non-targeted liposomes enhance safety, their uptake remains limited. In contrast, targeted liposomes achieve the greatest cytotoxic impact on breast cancer cells.

7.4 Cellular Uptake Studies

Through fluorescence microscopy, it was observed that cells exposed to ligand-targeted liposomes exhibited greater intracellular fluorescence intensity than those treated with non-targeted liposomes. This finding confirms that receptor-mediated endocytosis significantly enhances cellular internalization.

Figure 5: Fluorescence microscopy images showing enhanced cellular uptake of targeted liposomes in breast cancer cells.







7.5 Stability Study Results

Compared to traditional liposomes, surface-modified liposomes demonstrated enhanced stability, with only slight variations in particle size and encapsulation efficiency observed during storage. The process of PEGylation notably decreased drug leakage and extended the shelf-life.

8. DISCUSSION

8.1 Overview of Findings

The current study concentrated on creating and developing surface-modified liposomal drug delivery systems that encapsulate chemotherapeutic agents for precise delivery to breast cancer cells. The findings from physicochemical characterization, in-vitro drug release, cytotoxicity, cellular uptake, and stability assessments collectively highlight the advantages of targeted liposomal formulations compared to traditional free drug systems and non-targeted liposomes. The optimized formulations showed particle sizes in the nano-range (120–180 nm), low polydispersity indices (<0.25), and appropriate zeta potential values (−20 to −30 mV), suggesting uniform dispersion and colloidal stability. These physicochemical characteristics are essential for enabling passive targeting through the enhanced permeability and retention (EPR) effect, which permits nanocarriers to preferentially accumulate in tumor tissues due to leaky blood vessels and inadequate lymphatic drainage.

8.2 Impact of Surface Modification on Liposomal Performance

Altering the surface of liposomal drug delivery systems greatly improved their functional capabilities. Liposomes modified with PEG showed extended circulation times because of diminished opsonization and lessened absorption by the reticuloendothelial system (RES). This stealth characteristic allowed for greater tumor accumulation and enhanced pharmacokinetic profiles.

Liposomes with ligand functionalities exhibited even more promising therapeutic outcomes due to active targeting methods. Ligands like folic acid, antibodies, or peptides specifically attach to receptors that are overexpressed on breast cancer cells, promoting receptor-mediated endocytosis. This targeting approach boosts intracellular drug delivery, resulting in increased cytotoxic effects and lowered systemic toxicity.

Cellular uptake studies demonstrated that ligand-targeted liposomes were internalized significantly more than non-targeted ones. Analyses using fluorescence microscopy and flow cytometry showed stronger intracellular fluorescence in targeted formulations, confirming that receptor-mediated internalization was the main uptake route.

8.3 Drug Release Behavior and Therapeutic Implications

One of the key benefits of liposomal drug delivery systems is their ability to control and sustain drug release. In-vitro studies revealed that liposomes with surface modifications had extended release profiles, unlike free drug solutions that diffused quickly. This prolonged release is advantageous for maintaining therapeutic drug levels at the tumor site over longer durations.

Notably, a quicker drug release was noted in acidic conditions (pH 5.5), which simulate the tumor microenvironment. This pH-sensitive release indicates that surface-modified liposomes can achieve targeted drug delivery within tumor tissues or intracellular endosomal compartments, enhancing therapeutic effectiveness while reducing systemic exposure.

8.4 Enhanced Cytotoxicity Against Breast Cancer Cells

MTT assay-based cytotoxicity studies revealed that liposomal formulations with targeting capabilities exhibited markedly higher anticancer efficacy than both free drugs and non-targeted liposomes. This increased cytotoxic effect is due to several factors:

Enhanced cellular uptake through receptor-mediated endocytosis

Prolonged release of the drug within cells

Protection of the encapsulated drug from early degradation

Elevated drug concentration inside cells

These mechanisms collectively lead to better therapeutic results in breast cancer treatment. Additionally, targeted liposomes demonstrated selective toxicity towards cancer cells while minimizing harmful effects on normal cells, underscoring their safety benefits compared to traditional chemotherapy.

8.5 Stability Enhancement through Surface Engineering

Research on stability demonstrated that liposomes with surface modifications retained their particle size, zeta potential, and encapsulation efficiency over prolonged storage durations. The process of PEGylation was crucial in averting aggregation and minimizing drug leakage when stored at different temperatures. Ensuring stable liposomal formulations is vital for maintaining consistent therapeutic efficacy and extending shelf-life. The enhanced stability seen in modified liposomes suggests they are well-suited for large-scale manufacturing and clinical use.

8.6 Comparison with Conventional Chemotherapy

While conventional chemotherapeutic agents are effective, they frequently lack selectivity and can cause serious systemic side effects, including cardiotoxicity, myelosuppression, and gastrointestinal toxicity. Encapsulating these drugs in liposomes greatly enhances their therapeutic index by modifying their biodistribution and decreasing unintended exposure. Targeted liposomal drug delivery systems further amplify these advantages by facilitating active targeting of tumor cells. This dual targeting strategy, which combines passive and active targeting, maximizes drug concentration at the tumor site and reduces toxicity to healthy tissues.

8.7 Clinical and Translational Perspectives

The advancement of targeted liposomal drug delivery systems holds considerable promise for clinical oncology. A number of liposomal formulations have been approved by regulatory bodies for cancer treatment, illustrating the practical applicability of this method. Nonetheless, there are still hurdles to overcome, such as the scalability of production, consistency in ligand conjugation, long-term stability, and the pathways for regulatory approval. Future investigations should aim to refine ligand density, assess therapeutic effectiveness in vivo, and carry out clinical trials to confirm safety and efficacy in human subjects.

Table 6: Comparative Discussion of Free Drug, Conventional Liposomes, and Surface-Modified Liposomes

Parameter	Free Drug	Conventional Liposomes	Surface-Modified Targeted Liposomes
Selectivity	Low	Moderate (EPR effect)	High (active targeting)
Cytotoxicity	High systemic toxicity	Reduced toxicity	Enhanced cancer cell toxicity
Cellular Uptake	Passive diffusion	Limited uptake	Receptor-mediated enhanced uptake
Drug Release	Rapid	Sustained	Controlled and stimuli-responsive
Stability	Poor	Moderate	High stability
Therapeutic Index	Low	Improved	Significantly enhanced

Figure 6: Mechanistic representation of enhanced cytotoxicity of targeted liposomal formulations in breast cancer cells.







4

9. Conclusion

The creation of liposomal drug delivery systems that encapsulate chemotherapeutic agents and incorporate surface modifications is an innovative and promising approach for targeted breast cancer treatment. This study emphasizes the notable benefits of surface-engineered liposomes in enhancing drug stability, improving tumor-specific targeting, and boosting therapeutic effectiveness while reducing systemic toxicity.

The refined liposomal formulations exhibited favorable physicochemical properties, such as nano-sized particle distribution, high encapsulation efficiency, and advantageous zeta potential, which ensure effective tumor accumulation and stability. Surface modifications through PEGylation and ligand conjugation significantly extended circulation time, enhanced receptor-specific targeting, and facilitated

intracellular drug delivery via receptor-mediated endocytosis.

In-vitro cytotoxicity tests demonstrated that targeted liposomal formulations showed superior anticancer activity compared to free drugs and non-targeted liposomes. Cellular uptake studies further confirmed the increased internalization of ligand-modified liposomes in breast cancer cells, validating the success of active targeting strategies. Stability assessments indicated improved physicochemical stability and reduced drug leakage, highlighting the durability of surface-modified liposomal systems.

In summary, the combination of nanotechnology-based liposomal carriers with surface modification techniques provides a robust platform for precision chemotherapy in breast cancer treatment. Future investigations should concentrate on in-vivo pharmacokinetic and biodistribution studies, toxicity assessments, and clinical translation to fully harness the therapeutic potential of these targeted nanocarriers.

10. References

1. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews. 2013;65(1):36–48.

2. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery. 2014;13(11):813–827.

3. Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release. 2012;160(2):117–134.

4. Bozzuto G, Molinari A. Liposomes as nanomedical devices. International Journal of Nanomedicine. 2015;10:975–999.

5. Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 2015;6:286.

6. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science and clinical applications. International Journal of Nanomedicine. 2006;1(3):297–315.

7. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2(12):751–760.

8. Li J, Wang X, Zhang T, et al. A review on phospholipids and their main applications in drug delivery systems. Asian Journal of Pharmaceutical Sciences. 2015;10(2):81–98.

9. Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacological Reviews. 2016;68(3):701–787.

10. Kulkarni A, Avachat A. Liposomal drug delivery system: A review. Journal of Drug Delivery and Therapeutics. 2015;5(3):1–9.

11. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and Biopharmaceutics. 2009;71(3):409–419.

12. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS Journal. 2012;14(2):303–315.

13. Noble GT, Stefanick JF, Ashley JD, et al. Ligand-targeted liposome design: Challenges and

fundamental considerations. Trends in Biotechnology. 2014;32(1):32–45.

14. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annual Review of Medicine. 2012;63:185–198.

15. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chemical Reviews. 2015;115(19):10938–10966.

16. Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. Methods in Molecular Biology. 2017;1522:17–22.

17. Jain S, Jain NK. Engineered liposomes for targeted delivery of drugs to breast cancer cells. European Journal of Pharmaceutics and Biopharmaceutics. 2018;128:273–289.

18. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes for cancer therapy. Cancer Research. 2005;65(24):11631–11638.

19. Koudelka Š, Turánek J. Liposomal paclitaxel formulations. Journal of Controlled Release. 2012;163(3):322–334.

20. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 2005;4(2):145–160.